Cisco is the most overbought stock in the S&P 500. Here are the others.

Cisco jumped 22% over the week after better-than-expected fiscal Q3 results, a bullish Q4 outlook, and strong AI order momentum, putting the stock in overbought territory with an RSI of 90. Zoetis fell 10% after weaker-than-expected Q1 earnings and lowered full-year EPS and revenue guidance, leaving it oversold with an RSI of 14.4. The piece is primarily a technical/positioning screen for S&P 500 names rather than a market-wide catalyst.

Analysis

The dispersion is being driven less by fundamentals than by positioning forced through earnings gaps. Names with clean beats and elevated AI or defensive narratives are getting momentum-chased into overbought conditions, but that leaves them vulnerable to even modest de-risking once weekly call buying fades and systematic trend followers rebalance. In contrast, the oversold cohort looks less like classic mean-reversion setup and more like a repricing of forward estimates, so the key question is whether the selloff has already forced enough earnings compression to attract value and short-covering.

CSCO is the most fragile of the winners because the move was powered by a combination of guidance relief and an AI-exposure rerating, not by a structural step-up in near-term revenue growth. That means upside is likely to slow once the post-earnings gap is digested; any broad tech wobble or downgrade-to-neutral wave could trigger a 5-10% retrace quickly. By contrast, the weaker names are behaving differently: ZTS is not just oversold, it is signaling a demand elasticity problem in a category investors had treated as quasi-noncyclical, which can spill over to premium animal-health peers and vet-service names via a lower-price mix and slower clinic traffic.

The contrarian read is that the market may be overreacting on the downside to cyclical pressure in premium consumer and healthcare-adjacent franchises that still have durable brands, while underappreciating how fast earnings quality can decelerate when pricing power is tested. For DPZ and LULU, the cleaner trade may be not a blind bounce, but a wait-for-stabilization signal: one or two sessions of tight-range trading after capitulation would be more informative than chasing the first oversold bounce. The broader tape suggests a short-term mean-reversion market, but with skewed upside in the laggards only after investors see evidence that estimate cuts have slowed.

Key Decisions for Investors

• Short CSCO into strength for 1-2 weeks via call spread sale or outright short against a tech benchmark; target a 5-8% pullback, with risk capped if the AI order narrative reaccelerates.
• Initiate a pairs trade: long ZTS / short PANW for 2-6 weeks if the market continues rewarding recent winners and punishing post-earnings disappointments; this isolates valuation/flow reversal rather than beta.
• Watch DPZ for a delayed mean-reversion entry only after volume contracts and the stock stops making lower lows for 3-5 sessions; upside could be 6-10% from stabilization, but avoid catching a falling knife.
• Trim or hedge LULU exposure for the next 2-4 weeks until margin and demand commentary stops deteriorating; use put spreads rather than outright shorts to avoid squeeze risk if consumer sentiment improves.
• Keep HUM and CVS on a tactical relative-value list: if defensives keep lagging while rates fall or rotate lower, they can become a crowded defensive long, but entry should wait for confirmation that positioning has reset.